Literature DB >> 23486070

Is there an association between HIV-1 genital shedding and cervical intraepithelial neoplasia 2/3 among women on antiretroviral therapy?

Megan Justine Huchko1, Victoria Woo, Teri Liegler, Anna Leddy, Karen Smith-McCune, George F Sawaya, Elizabeth A Bukusi, Craig R Cohen.   

Abstract

OBJECTIVE: Given the high prevalence of cervical intraepithelial neoplasia (CIN) grade 2/3 among HIV-infected women, we sought to examine the relationship between CIN 2/3 and HIV-1 genital shedding among women on highly active antiretroviral therapy (HAART).
MATERIALS AND METHODS: Paired plasma and cervical wick specimens for HIV-1 RNA measurements were obtained from 44 HIV-infected women with biopsy-confirmed CIN 2/3 (cases) and 44 age-matched HIV-infected women with normal cervical findings on colposcopy (controls). All subjects tested negative for sexually transmitted infections and had been stable on HAART for at least 3 months. HIV-1 viral load was measured in both blood and cervical specimens using commercial real-time polymerase chain reaction assays.
RESULTS: Cervical intraepithelial neoplasia 2/3 was not significantly associated with the detection or magnitude of plasma or cervical HIV-1 RNA shedding. HIV was detected in the plasma in 10 cases (23%) and 10 controls (25%) (odds ratio = 1.0; 95% confidence interval = 0.33-3.1). Cervical HIV-1 was detected in 6 cases (13.6%) and 9 controls (20.4%) (odds ratio = 0.61; 95% confidence interval = 0.20-1.90). Mean HIV-1 concentration in cervical secretions among women with CIN 2/3 who shed was 2.93 log10 copies versus 2.72 among controls (p = .65).
CONCLUSIONS: Among women on HAART, we found no relationship between CIN 2/3 and HIV-1 genital shedding.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23486070      PMCID: PMC3690152          DOI: 10.1097/LGT.0b013e3182712286

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  22 in total

1.  Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.

Authors:  S Cu-Uvin; A M Caliendo; S Reinert; A Chang; C Juliano-Remollino; T P Flanigan; K H Mayer; C C Carpenter
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

2.  Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding.

Authors:  Susan M Graham; Sarah E Holte; Norbert M Peshu; Barbra A Richardson; Dana D Panteleeff; Walter G Jaoko; Jeckoniah O Ndinya-Achola; Kishorchandra N Mandaliya; Julie M Overbaugh; R Scott McClelland
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

3.  Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study.

Authors:  Odile Launay; Michel Tod; Inga Tschöpe; Ali Si-Mohamed; Linda Bélarbi; Charlotte Charpentier; Cécile Goujard; Anne-Marie Taburet; Olivier Lortholary; Valériane Leroy; Laurent Bélec
Journal:  Antivir Ther       Date:  2011

4.  Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.

Authors:  Nonhlanhla N Mkhize; Pamela P Gumbi; Lenine J Liebenberg; Yuan Ren; Peter Smith; Lynette Denny; Jo-Ann S Passmore
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

5.  Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration.

Authors:  T C Wright; S Subbarao; T V Ellerbrock; J L Lennox; T Evans-Strickfaden; D G Smith; C E Hart
Journal:  Am J Obstet Gynecol       Date:  2001-02       Impact factor: 8.661

6.  Human immunodeficiency virus type 1-related nucleic acids and papillomavirus DNA in cervicovaginal secretions of immunodeficiency virus-infected women.

Authors:  A Spinillo; M Debiaggi; F Zara; A De Santolo; F Polatti; G Filice
Journal:  Obstet Gynecol       Date:  2001-06       Impact factor: 7.661

7.  Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding.

Authors:  James Homans; Shawna Christensen; Tracey Stiller; Chia-Hao Wang; Wendy Mack; Kathryn Anastos; Howard Minkoff; Mary Young; Ruth Greenblatt; Mardge Cohen; Howard Strickler; Roksana Karim; Lashonda Yvette Spencer; Eva Operskalski; Toinette Frederick; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2012-05-01       Impact factor: 3.731

8.  Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA.

Authors:  J Kreiss; D M Willerford; M Hensel; W Emonyi; F Plummer; J Ndinya-Achola; P L Roberts; J Hoskyn; S Hillier; N Kiviat
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

9.  Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts.

Authors:  Jenell S Coleman; Jane Hitti; Elizabeth A Bukusi; Christina Mwachari; Angela Muliro; Rosemary Nguti; Reggie Gausman; Sarah Jensen; Dorothy Patton; David Lockhart; Robert Coombs; Craig R Cohen
Journal:  AIDS       Date:  2007-03-30       Impact factor: 4.177

10.  Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies.

Authors:  Josè Ramòn Fiore; Barbara Suligoi; Annalisa Saracino; Mariantonietta Di Stefano; Roberto Bugarini; Achiropita Lepera; Anna Favia; Laura Monno; Gioacchino Angarano; Giuseppe Pastore
Journal:  AIDS       Date:  2003-10-17       Impact factor: 4.177

View more
  2 in total

1.  Human Papillomavirus (HPV) Infections and the Importance of HPV Vaccination.

Authors:  Chia-Ching J Wang; Joel M Palefsky
Journal:  Curr Epidemiol Rep       Date:  2015-03-26

2.  Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer.

Authors:  Jeny Ghartey; Andrea Kovacs; Robert D Burk; L Stewart Massad; Howard Minkoff; Xianhong Xie; Gypsyamber Dʼsouza; Xiaonan Xue; D Heather Watts; Alexandra M Levine; Mark H Einstein; Christine Colie; Kathryn Anastos; Isam-Eldin Eltoum; Betsy C Herold; Joel M Palefsky; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.